2,277 results on '"Ray-Coquard, Isabelle"'
Search Results
2. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
3. Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial
4. Correction: Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
5. Cancers de l’ovaire. Des nouvelles molécules pour chaque type histologique ou moléculaire, une avancée vers plus de guérison ?
6. Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer
7. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
8. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
9. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
10. Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor
11. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer
12. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
13. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
14. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
15. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
16. Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study
17. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
18. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
19. CREB fusion–associated epithelioid mesenchymal neoplasms of the female adnexa: three cases documenting a novel location of an emerging entity and further highlighting an ambiguous misleading immunophenotype
20. What is the Optimal Adjuvant Chemotherapy Regimen for Primary Granulosa Cell Tumor?
21. What is the Best Front-line Maintenance Therapy for HRD-positive Ovarian Cancer?
22. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2
23. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
24. Selinexor in patients with advanced and recurrent endometrial cancer
25. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
26. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
27. Do surgeons overestimate diaphragmatic peritoneal disease in interval debulking surgery of ovarian cancer?
28. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial
29. Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers
30. Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study
31. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
32. Sarcomes du stroma endométrial de bas grade : référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG
33. Avancées thérapeutiques dans la prise en charge des tumeurs rares malignes ovariennes
34. Adénosarcomes mullériens de l’utérus – référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG
35. Sarcomes utérins du stroma de haut grade et sarcomes indifférenciés – Référentiels de prise en charge du Groupe Sarcome Français et du Groupe des Tumeurs Rares Gynécologiques
36. Comparison between exclusive (chemo)radiation and surgery or induction chemotherapy as first curative treatment for localized or locally advanced head and neck squamous cell carcinomas (L(A)-HNSCC): Sub-analysis of the EPOCKS study
37. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice
38. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
39. Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial
40. Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
41. The KAT6B::KANSL1 Fusion Defines a New Uterine Sarcoma With Hybrid Endometrial Stromal Tumor and Smooth Muscle Tumor Features
42. Diagnostic des sarcomes utérins et tumeurs mésenchymateuses utérines rares à potentiel de malignité. Référentiels du Groupe Sarcome Français et des Tumeurs Rares Gynécologiques
43. Gynecological carcinosarcomas: Overview and future perspectives
44. Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.
45. Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.
46. Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from the randomized phase II trial CHIVA (GINECO).
47. The French multicentric molecular analysis platforms and personalized medicine trials MOST, MOST Plus and MEGAMOST
48. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study
49. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
50. Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.